Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure

Endocrine

Volumn 57, Issue 3, 2017, Pages 464-473

  Arturi, F ^a   Succurro, E ^a   Miceli, S ^a   Cloro, C ^b   Ruffo, M ^a   Maio, R ^c   Perticone, M ^a   Sesti, G ^a   Perticone, F ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Unit of Cardiology SS Annunziata Hospital of Cosenza   (Italy)

^c Policlinico Mater Domini   (Italy)

Author keywords

Cardiac function; Chronic heart failure; Glucagon like peptide 1; Left ventricular ejection fraction; Liraglutide; Type 2 diabetes

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; CARDIOTONIC AGENT; INCRETIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FUNCTIONAL STATUS; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART FUNCTION; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; LABORATORY TEST; MALE; MEDICAL HISTORY; NEW YORK HEART ASSOCIATION CLASS; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIX MINUTE WALK TEST; TREATMENT DURATION; BLOOD; COMBINATION DRUG THERAPY; COMPLICATION; DIABETIC CARDIOMYOPATHY; DRUG EFFECT; HEART; HYPERGLYCEMIA; HYPOGLYCEMIA; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; BIOMARKERS; CARDIOTONIC AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DRUG THERAPY, COMBINATION; FEMALE; HEART; HEART FAILURE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN GLARGINE; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; SITAGLIPTIN PHOSPHATE; STROKE VOLUME; SULFONYLUREA COMPOUNDS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84994477352     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-016-1166-4     Document Type: Article

References (48)

1. I.S. Thrainsdottir, T. Aspelund, G. Thorgeirsson, V. Gudnason, T. Hardarson, K. Malmberg, G. Sigurdsson, L. Rydèn, The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 28, 612–616 (2005)
2. W. Dinh, M. Lankisch, W. Nickl, D. Scheyer, T. Scheffold, F. Kramer, F. Kramer, T. Krahn, R.M. Klein, M.C. Barroso, Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study. Cardiovasc. Diabetol. 9, 63–74 (2010)
3. S. Rubler, J. Dlugash, Y.Z. Yuceoglu, T. Kumral, A.D. Branwood, A. Grishman, New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30, 595–602 (1972)
4. B. Rodrigues, M.C. Cam, J.H. McNeill, Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J. Mol. Cell. Cardiol. 27, 169–179 (1995)
5. L.H. Opie, D.M. Yellon, B.J. Gersh, Controversies in the cardiovascular management of type 2 diabetes. Heart. 97, 6–14 (2011)
6. J.D. Schilling, D.L. Mann, Diabetic cardiomyopathy: bench to bedside. Heart Fail. Clin. 8, 619–631 (2012)
7. D.L. Bhatt, D.P. Chew, C. Grines, D. Mukherjee, M. Leesar, I.C. Gilchrist, J.C. Corbelli, J.C. Blankenship, A. Eres, S. Steinhubl, W.A. Tan, J.R. Resar, A. AlMahameed, A. Abdel-Latif, W.H. Tang, D. Brennan, E. McErlean, S.L. Hazen, E.J. Topol, Peroxisome proliferator-activated receptor gamma agonists for the prevention of adverse events following percutaneous coronary revascularization-results of the PPAR study. Am. Heart J. 154, 137–143 (2007)
8. J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. Erdmann, M. Massi-Benedetti, I.K. Moules, A.M. Skene, M.H. Tan, P.J. Lefèbvre, G.D. Murray, E. Standl, R.G. Wilcox, L. Wilhelmsen, J. Betteridge, K. Birkeland, A. Golay, R.J. Heine, L. Korànyi, M. Laakso, M. Mokàn, A. Norkus, V. Pirags, T. Podar, A. Scheen, W. Scherbaum, G. Schernthaner, O. Schmitz, J. Skrha, U. Smith, J. taton; PROactive Investigators., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial. Lancet. 366, 1279–1289 (2005)
9. R.M. Lago, P.P. Singh, R.W. Nesto, Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 370, 1129–1136 (2007)
10. D.T. Eurich, S.R. Majumdar, F.A. McAlister, R.T. Tsuyuki, J.A. Johnson, Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 28, 2345–2351 (2005)
11. G.A. Nichols, C.E. Koro, C.M. Gullion, S.A. Ephross, J.B. Brown, The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab. Res. Rev. 21, 51–57 (2005)
12. D.T. Eurich, F.A. McAlister, D.F. Blackburn, S.R. Majumdar, R.T. Tsuyuki, J. Varney, J.A. Johnson, Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Br. Med. J. 8(335), 497 (2007)
13. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, B. Hirshberg, P. Ohman, R. Frederich, S.D. Wiviott, E.B. Hoffman, M.A. Cavender, J.A. Udell, N.R. Desai, O. Mosenzon, D.K. McGuire, K.K. Ray, L.A. Leiter, I. Raz; SAVOR-TIMI 53 Steering Committee and Investigators., Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317–1326 (2013)
14. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris, A.T. Perez, P.R. Fleck, C.R. Mehta, S. Kupfer, C. Wilson, W.C. Cushman, F. Zannad; EXAMINE Investigators., Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369, 1327–1335 (2013)
15. J.B. Green, M.A. Bethel, P.W. Armstrong, J.B. Buse, S.S. Engel, J. Garg, R. Josse, K.D. Kaufman, J. Koglin, S. Korn, J.M. Lachin, D.K. McGuire, M.J. Pencina, E. Standl, P.P. Stein, S. Suryawanshi, F. Van de Werf, E.D. Peterson, R.R. Holman; TECOS Study Group., Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373, 232–242 (2015)
16. M.A. Pfeffer, B. Claggett, R. Diaz, K. Dickstein, H.C. Gerstein, L.V. Køber, F.C. Lawson, L. Ping, X. Wei, E.F. Lewis, A.P. Maggioni, J.J. McMurray, J.L. Probstfield, M.C. Riddle, S.D. Solomon, J.C. Tardif; ELIXA Investigators., Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247–2257 (2015)
17. B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O.E. Johansen, H.J. Woerle, U.C. Broedl, S.E. Inzucchi; EMPA REG OUTCOME Investigators., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015)
18. S.P. Marso, G.H. Daniels, K. Brown-Frandsen, P. Kristensen, J.F. Mann, M.A. Nauck, S.E. Nissen, S. Pocock, N.R. Poulter, L.S. Ravn, W.M. Steinberg, M. Stockner, B. Zinman, R.M. Bergenstal, J.B. Buse; LEADER Steering Committee on Behalf of the LEADER Trial Investigators, Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. [Epub ahead of print] 375, 311–22 (2016)
19. D.J. Drucker, M.A. Nauck, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 368, 1696–1705 (2006)
20. J.R. Ussher, D.J. Drucker, Cardiovascular biology of the incretin system. Endocr. Rev. 33, 187–215 (2012)
21. E. Montanya, G. Sesti, A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin. Ther. 31, 2472–2488 (2009)
22. M. Nauck, A. Frid, K. Hermansen, N.S. Shah, T. Tankova, I.H. Mitha, M. Ztravkovic, M. During, D.R. Matthews; LEAD-2 Study Group., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care. 32, 84–90 (2009)
23. J.B. Buse, J. Rosenstock, G. Sesti, W.E. Schmidt, E. Montanya, J.H. Brett, M. Zychma, L. Blonde; LEAD-6 Study Group., A study of two glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomized, 26-week, open-label trial (LEAD-6). Lancet. 374, 39–47 (2009)
24. R.E. Amori, J. Lau, A.G. Pittas, Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 298, 194–206 (2007)
25. S.E. Inzucchi, D.K. McGuire, New drugs for the treatment of diabetes. Part II: incretin-based therapy and beyond. Circulation 117, 574–584 (2008)
26. I. Thrainsdottir, K. Malmberg, A. Olsson, M. Gutniak, L. Rydén, Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab. Vasc. Dis. Res. 1, 40–43 (2004)
27. L.A. Nikolaidis, S. Mankad, G. Sokos, G. Miske, A. Shah, D. Elahi, R.P. Shannon, Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 109, 962–965 (2004)
28. G. Sokos, L.A. Nikolaidis, S. Mankad, D. Elahi, R.P. Shannon, Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Cardiac. Fail. 12, 694e699 (2006)
29. L.M. McCormick, P.M. Heck, L.S. Ring, A.C. Kydd, S.J. Clarke, S.P. Hoole, D.P. Dutka, Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc. Diabetol. 8(14), 102 (2015)
30. W.R. Chen, X.Q. Shen, Y. Zhang, Y.D. Chen, G. Qian, J. Wang, J.J. Yang, Z.F. Wang, F. Tian, Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine. 52, 516–526 (2015) doi:10.1007/s12020-015-0798-0
31. M. Halbirk, H. Nørrelund, N. Møller, J.J. Holst, O. Schmitz, R. Nielsen, J.E. Nielsen-Kudsk, S.S. Nielsen, T.T. Nielsen, H. Eiskjaer, H.E. Bøtker, H. Wiggers, Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am. J. Physiol. Heart. Circ. Physiol. 298(3), H1096–102 (2010). doi:10.1152/ajpheart.00930.2009
32. D. Nathanson, B. Ullman, U. Löfström, A. Hedman, M. Frick, A. Sjöholm, T. Nyström, Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia. 55, 926–935 (2012). doi:10.1007/s00125-011-2440-x
33. N. Mikhail, Effects of incretin-based therapy in patients with heart failure and myocardial infarction. Endocrine. 47, 21–28 (2014). doi:10.1007/s12020-014-0175-4
34. K.B. Margulies, K.J. Anstrom, M.M. Redfield, et al. A randomized trial of liraglutide for high-risk heart failure patients with reduced ejection fraction (FIGHT). American Heart Association 2015 Scientific Sessions; 8 November 2015; Orlando, Florida. Abstract 20102 (2015)
35. M.H. Noyan-Ashraf, M.A. Momen, K. Ban, A.M. Sadi, Y.Q. Zhou, A.M. Riazi, L.L. Baggio, R.M. Henkelman, M. Husain, D.J. Drucker, GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58, 975–983 (2009)
36. S. Ravassa, A. Zudaire, R.D. Carr, J. Díez, Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 300, 1361–1372 (2011)
37. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, M. Husain, Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and –independent pathways. Circulation. 117, 2340–2350 (2008)
38. T. Zhao, P. Parikh, S. Bhashyam, H. Bolukoglu, I. Poornima, Y.T. Shen, R.P. Shannon, Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther. 317, 1106–1113 (2006)
39. A. Basu, N. Charkoudian, W. Schrage, R.A. Rizza, R. Basu, M.J. Joyner, Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am. J. Physiol. Endocrinol. Metab. 293, 1289–1295 (2007)
40. L.A. Nikolaidis, D. Elahi, T. Hentosz, A. Doverspike, R. Huerbin, L. Zourelias, C. Stolarski, Y.T. Shen, R.P. Shannon, Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 110, 955–961 (2004)
41. A. Ceriello, K. Esposito, R. Testa, A.R. Bonfigli, M. Marra, D. Giugliano, The possible protective role of glucagon like peptide 1 on endothelium during the meal and evidence for an “endothelial resistance” to glucagon-like peptide 1 in diabetes. Diabetes Care. 34, 697–702 (2011)
42. K. Okada, K. Kotani, H. Yagyu, A. Ando, J. Osuga, S. Ishibashi, Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus. Endocrine. 47, 962–964 (2014). doi:10.1007/s12020-014-0246-6.
43. K.E. Mayo, L.J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, D.J. Drucker, International union of pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev 55, 167–194 (2003)
44. B. Thorens, Expression cloning of the pancreatic-cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc. Natl. Acad. Sci USA 89, 8641–8645 (1992)
45. L.A. Nikolaidis, D. Elahi, Y.T. Shen, R.P. Shannon, Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 289, 2401–2408 (2005)
46. C.F. Deacon, A.H. Johnsen, J.J. Holst, Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80, 952–957 (1995)
47. E. Tomas, J.A. Wood, V. Stanojevic, J.F. Habener, Glucagon-like peptide-1(9-36) amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. Diabetes Obes. Metab. 13, 26–33 (2011)
48. I.B. Poornima, S. Bhashyam, P. Parikh, H. Bolukoglu, R. Shannon, Chronic glucagon-like peptide-1 infusion sustains left ventricular function and prolongs survival in spontaneously hypertensive, heart failure prone rats. Circ. Heart Fail. 1, 153–160 (2008)